Repro Med Systems Inc (REPR)

[blue_skies]

I should have read the headlines for conference abstracts before prior posting. Note highlighted at bottom. The super26 needle set study results will be release at conference. My guess is this is why all hand are on deck there!! Major product lunch is imminent and close?!

https://ignsconference.com/36-study-to-evaluate-patient-centered-outcomes-and-infusion-parameters-using-the-rms-highflo-super-26-needle-set-vs-rms-standard-highflo-26gauge-needle-set-in-patients-with-primary-immunodeficiency/

The Super 26 needle is FDA-cleared but has yet to be released for commercial or clinical use on a larger scale. Patient-completed surveys captured infusion parameters, satisfaction scores, and incidental (minor) adverse events at each of 8 infusions (4 infusions with standard 26g needles vs. 4 infusions with Super 26g needles). Each subject will serve as his/her own control. Paired analysis of variance will be used to assess for differences in continuous variables and chi squared tests will be used to assess dichotomous variables. Results: Study is currently ongoing and results will be available at the time of conference presentation. Discussion: Study is currently ongoing and discussion will be available at the time of conference presentation. Conclusions: Study is currently ongoing and conclusion will be available at the time of conference presentation.[color=red][/color]